Anti-Colorectal Cancer Compound Library

Sizes available: 

10 mM *30µl, 10 mM *50µl, 10 mM *100µl, 2*10 mM *100µl, 10 mM *250µl

Please contact us for price or customized libraries!

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1450 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research. MCE Anti-Colorectal Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1407 compounds supplied in 10 mM solution, 40 compounds supplied in 2 mM solution and 3 compounds supplied in 3 mg/mL solution. For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.